Citation: J. Glaspy et D. Bagga, DIETARY MODULATION OF OMEGA-3 OMEGA-6 POLYUNSATURATED FATTY-ACID RATIOS IN PATIENTS WITH BREAST-CANCER - RESPONSE/, Journal of the National Cancer Institute, 90(8), 1998, pp. 630-631
Citation: J. Glaspy, HEMATOLOGICAL AND QUALITY-OF-LIFE (QOL) OUTCOMES IN ANEMIC LUNG-CANCER PATIENTS TREATED WITH EPOETIN-ALPHA, Annals of oncology, 9, 1998, pp. 683-683
Citation: J. Glaspy et Gd. Demetri, HEMATOLOGICAL AND QUALITY-OF-LIFE (QOL) OUTCOMES IN ANEMIC CANCER-PATIENTS TREATED, WITH EPOETIN-ALPHA, British Journal of Haematology, 102(1), 1998, pp. 336-336
Authors:
TOLOZA EM
HUNT K
MILLER AR
MCBRIDE W
LAU R
SWISHER S
RHOADES K
ARTHUR J
CHOI J
CHEN L
CHANG PP
CHEN A
GLASPY J
ECONOMOU JS
Citation: Em. Toloza et al., TRANSDUCTION OF MURINE AND HUMAN TUMORS USING RECOMBINANT ADENOVIRUS VECTORS, Annals of surgical oncology, 4(1), 1997, pp. 70-79
Authors:
NGUYEN M
TRAN C
BARSKY S
SUN JR
MCBRIDE W
PEGRAM M
PIETRAS R
LOVE S
GLASPY J
Citation: M. Nguyen et al., THALIDOMIDE AND CHEMOTHERAPY COMBINATION - PRELIMINARY-RESULTS OF PRECLINICAL AND CLINICAL-STUDIES, International journal of oncology, 10(5), 1997, pp. 965-969
Authors:
RUSTHOVEN JJ
DEVRIES EGE
DALE DC
PICCART M
GLASPY J
HAMILTON A
Citation: Jj. Rusthoven et al., CONSENSUS ON THE USE OF NEUTROPHIL-STIMULATING HEMATOPOIETIC GROWTH-FACTORS IN CLINICAL-PRACTICE - AN INTERNATIONAL VIEWPOINT, International journal of antimicrobial agents, 8(4), 1997, pp. 263-275
Authors:
GLASPY J
BUKOWSKI R
STEINBERG D
TAYLOR C
TCHEKMEDYIAN S
VADHANRAJ S
Citation: J. Glaspy et al., IMPACT OF THERAPY WITH EPOETIN ALFA ON CLINICAL OUTCOMES IN PATIENTS WITH NONMYELOID MALIGNANCIES DURING CANCER-CHEMOTHERAPY IN COMMUNITY ONCOLOGY PRACTICE, Journal of clinical oncology, 15(3), 1997, pp. 1218-1234
Authors:
CHAP L
SHPINER R
LEVINE M
NORTON L
LILL M
GLASPY J
Citation: L. Chap et al., PULMONARY TOXICITY OF HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER - A NONINVASIVE APPROACH TO DIAGNOSIS AND TREATMENT, Bone marrow transplantation, 20(12), 1997, pp. 1063-1067
Authors:
HOH CK
GLASPY J
ROSEN P
DAHLBOM M
LEE SJ
KUNKEL L
HAWKIN RA
MADDAHI J
PHELPS ME
Citation: Ck. Hoh et al., WHOLE-BODY FDG-PET IMAGING FOR STAGING OF HODGKINS-DISEASE AND LYMPHOMA, The Journal of nuclear medicine, 38(3), 1997, pp. 343-348
Citation: J. Glaspy, THE IMPACT OF EPOETIN ALFA ON QUALITY-OF-LIFE DURING CANCER-CHEMOTHERAPY - A FRESH LOOK AT AN OLD PROBLEM, Seminars in hematology, 34(3), 1997, pp. 20-26
Authors:
FANUCCHI M
GLASPY J
CRAWFORD J
GARST J
FIGLIN R
SHERIDAN W
MENCHACA D
TOMITA D
OZER H
HARKER L
Citation: M. Fanucchi et al., EFFECTS OF POLYETHYLENE GLYCOL-CONJUGATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR ON PLATELET COUNTS AFTER CHEMOTHERAPY FOR LUNG-CANCER, The New England journal of medicine, 336(6), 1997, pp. 404-409
Authors:
GLASPY J
CHAP L
PRAGER D
NORTON L
LILL M
SHERIDAN W
Citation: J. Glaspy et al., THE INCIDENCE OF THROMBOTIC EVENTS IN WOMEN UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDC) WITH PROGENITOR-CELL SUPPORT FOR BREAST-CANCER, Blood, 90(10), 1997, pp. 4365-4365
Authors:
BOLWELL B
VREDENBURGH J
OVERMOYER B
GILBERT C
CHAP L
MENCHACA D
SCARLATA D
GLASPY J
Citation: B. Bolwell et al., SAFETY AND BIOLOGIC EFFECT OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (PEG-RHUMGDF) IN BREAST CANTER PATIENTS FOLLOWING AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION (PBPC), Blood, 90(10), 1997, pp. 756-756
Authors:
VREDENBURGH J
GLASPY J
BOLWELL B
DEMETRI GD
KIN B
JELACAMAXWELL K
SHPALL EJ
Citation: J. Vredenburgh et al., THE INCIDENCE OF THROMBOTIC AND EMBOLIC EVENTS IN CONTROLLED CLINICAL-TRIALS OF BREAST-CANCER (CA) PATIENTS (PTS) UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDC) WITH THE STAMP-I REGIMEN AND AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION, Blood, 90(10), 1997, pp. 972-972
Authors:
GLASPY J
LU ZJ
WHEELER C
BROWN R
SHEA T
MANGAN K
LEMAISTRE C
LONG G
PECORA A
YANOVICH S
ERDER MH
CHAN W
SHPALL EJ
Citation: J. Glaspy et al., ECONOMIC RATIONALE FOR INFUSING OPTIMAL NUMBERS OF CD34(-BLOOD PROGENITOR-CELL TRANSPLANTS (PBPCT)() CELLS IN PERIPHERAL), Blood, 90(10), 1997, pp. 1646-1646
Authors:
GLASPY J
VREDENBURGH J
DEMETRI GD
CHAP L
GILBERT C
OVERMOYER B
WARREN DL
BERG R
SCARLATA D
MENCHACA D
BOLWELL B
Citation: J. Glaspy et al., EFFECTS OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (PEG-RHUMGDF) BEFORE HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) SUPPORT, Blood, 90(10), 1997, pp. 2582-2582
Authors:
TOLOZA EM
HUNT K
SWISHER S
MCBRIDE W
LAU R
PANG S
RHOADES K
DRAKE T
BELLDEGRUN A
GLASPY J
ECONOMOU JS
Citation: Em. Toloza et al., IN-VIVO CANCER GENE-THERAPY WITH A RECOMBINANT INTERLEUKIN-2 ADENOVIRUS VECTOR, Cancer gene therapy, 3(1), 1996, pp. 11-17
Citation: C. Emmanouilides et J. Glaspy, OPPORTUNISTIC INFECTIONS IN ONCOLOGIC PATIENTS, Hematology/oncology clinics of North America, 10(4), 1996, pp. 841
Authors:
SEU P
BUI LA
BUTTERFIELD LH
LAU R
GLASPY J
MCBRIDE WH
KALDAS F
BUSUTTIL RW
ECONOMOU JS
Citation: P. Seu et al., GENE-THERAPY OF HEPATOCELLULAR-CARCINOMA (HCC) - EFFICACY OF AN ADENOVIRUS VECTOR WITH CANCER-SPECIFIC GENE-EXPRESSION, Hepatology, 24(4), 1996, pp. 477-477
Authors:
ECONOMOU JS
BELLDEGRUN AS
GLASPY J
TOLOZA EM
FIGLIN R
HOBBS J
MELDON N
KABOO R
TSO CL
MILLER A
LAU R
MCBRIDE W
MOEN RC
Citation: Js. Economou et al., IN-VIVO TRAFFICKING OF ADOPTIVELY TRANSFERRED INTERLEUKIN-2 EXPANDED TUMOR-INFILTRATING LYMPHOCYTES AND PERIPHERAL-BLOOD LYMPHOCYTES - RESULTS OF A DOUBLE GENE MARKING TRIAL, The Journal of clinical investigation, 97(2), 1996, pp. 515-521
Citation: J. Glaspy, PREDICTING CLINICAL OUTCOME OF EPOETIN ALFA THERAPY BY TUMOR TYPE IN ANEMIC CANCER-PATIENTS RECEIVING CHEMOTHERAPY, Blood, 88(10), 1996, pp. 3285-3285
Citation: Sl. Capone et al., NUTRITIONAL INTERVENTION FOR THE MANAGEMENT OF MINIMAL RESIDUAL DISEASE FOLLOWING HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL PROGENITOR-CELL SUPPORT FOR BREAST-CANCER, Blood, 88(10), 1996, pp. 502-502
Authors:
GLASPY J
BUKOWSKI R
STEINBERG D
TAYLOR CW
VADHANRAJ S
DANNA RP
SAROKHAN B
LONCZAK L
MCNEILL M
Citation: J. Glaspy et al., A PHASE-IV STUDY OF EPOETIN ALFA EXAMINING CLINICAL OUTCOMES IN ANEMIC CANCER-PATIENTS RECEIVING CHEMOTHERAPY, European journal of cancer, 31A, 1995, pp. 233-233